Triplet chemotherapy with cisplatin, docetaxel, and irinotecan for patients with recurrent or refractory non-small cell lung cancer

Acta Medica Okayama

Volumn 64, Issue 1, 2010, Pages 33-37

  Fujimoto, Nobukazu ^a   Kiura, Katsuyuki ^a   Takigawa, Nagio ^b   Fujiwara, Yoshiro ^a   Toyooka, Shinichi ^b   Umemura, Shigeki ^a   Tabata, Masahiro ^a   Ueoka, Hiroshi ^a   Tanimoto, Mitsune ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Cisplatin; Docetaxel; Gefitinib; Irinotecan; Triplet chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CISPLATIN; DOCETAXEL; DRUG DERIVATIVE; GEFITINIB; IRINOTECAN; QUINAZOLINE DERIVATIVE; TAXOID;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; FEMALE; FOLLOW UP; HUMAN; LARGE CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; MIDDLE AGED; MORTALITY; RETROSPECTIVE STUDY; SIGNET RING CARCINOMA; SQUAMOUS CELL CARCINOMA; SURVIVAL; TUMOR RECURRENCE;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SIGNET RING CELL; CARCINOMA, SQUAMOUS CELL; CISPLATIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; QUINAZOLINES; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TAXOIDS;

EID: 77952782303     PISSN: 0386300X     EISSN: 0386300X     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, Olak J, Stover D, Strawn JR, Turrisi AT and Somerfield MR; American Society of Clinical Oncology: Treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol (2003)22: 330-353.
2. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y and Berille J: Prospective randomized trial of docetaxel versus supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol (2000) 18: 2095-2103.
3. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F and Hammershaimb L: Randomized phase III trial of docetaxel versus vinorelbine or ifosf-amide in patients with advanced non-small lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol (2000) 18: 2354-2362.
4. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L and Bunn PA Jr: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol (2004)22: 1589-1597.
5. Kim ES, HirshV, Mok T, Socinski MA, Gervais R, Wu YL, Li LY, Watkins CL, Sellers MV, Lowe ES, Sun Y, Liao ML, Osterlind K, Reck M, Armour AA, Shepherd FA, Lippman SM and Douillard JY: Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet (2008)372: 1809-1818.
6. Kiura K, Takigawa N, Segawa Y, Tabata M, Shibayama T, Gemba K, Bessho A, Fujimoto N, Takata I, Hotta K, Fujiwara K, Tokuda Y, Kuyama S, Shinkai T, Ueoka H and Tanimoto M; Okayama Lung Cancer Study Group: Triple combination chemotherapy with cisplatin, docetaxel, and irinotecan for advanced non-small cell lung cancer: a phase l/ll trial. J Thorac Oncol (2007)2: 44-50.
7. Aoe K, Kiura K, Ueoka H, Tabata M, Matsumura T, Chikamori M, Matsushita A, Kohara H and Harada M: Effect of docetaxel with cisplatin or vinorelbine on lung cancer cell lines. Anticancer Res (1999) 19: 291-299.
8. Kohara H, Tabata M, Kiura K, Ueoka H, Kawata K, Chikamori M, Aoe K, Chikamori K, Matsushita A and Harada M: Synergistic effects of topoisomerase I inhibitor, 7-ethyl-10-hydroxycamptothe-cin, and irradiation in a cisplatin-resistant human small cell lung cancer cell line. Clin Cancer Res (2002) 287-292.
9. Matsushita A, Tabata M, Ueoka H, Kiura K, Shibayama T, Aoe K, Kohara H and Harada M: Establishment of a drug sensitivity panel using human lung cancer cell lines. Acta Med Okayama (1999) 53: 67-75.
10. McVie JG: Cancer of the lung and pleura; in Manual of Clinical Oncology, Hossfeld DK, Sherman CD, Love RR eds, 6th Ed, Springer-Verlag, Berlin (1990) pp 217-227
11. Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, Nishiwaki Y, Saijo N, Ariyoshi Y and Fukuoka M: Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol (2007) 18: 317-323.
12. Hotta K, Kiura K, Toyooka S, Takigawa N, Soh J, Fujiwara Y, Tabata M, Date H and Tanimoto M: Clinical significance of epidermal growth factor receptor gene mutations on treatment outcome after first-line cytotoxic chemotherapy in Japanese patients with non-small cell lung cancer. J Thorac Oncol (2007) 2: 632-637.